Thierry André, MD

Flash: How to Integrate CPI in MSI-H Rectal Cancer - Double CPI? Duration? Role of RT?

Thierry André , MD;

07/07/2023

Debate: Neoadjuvant Therapy in Locally Advanced Colon Cancer - NO

Thierry André , MD;

07/07/2023

Videos

Integrating Checkpoint Inhibitors into Treatment of Patients MSI-High Rectal Cancer

08/24/2023

Thierry André , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Thierry André, MD, discussed the use of checkpoint inhibitors for patients with MSI-high colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Videos

Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer

01/23/2024

Thierry André , MD;

Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.

Thierry Andre, MD, discusses the...

01/23/2024

Oncology

How to Improve the Results with IO Agents in MSI GI Cancer ?

Thierry André , MD;

07/06/2019

Can we refine the selection for adjuvant treatment in stage III colon cancer?

Thierry André , MD;

07/09/2018

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset

Background Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in various tumour types. Larotrectinib is a first-in-class, highly selective tropomyosin rece...

Jordan D. Berlin ;

C. Mussi ;

D. Oh ;

Serge Leyvraz ;

A. Drilon ;

Maria de Miguel ;

Yongmei Liu ;

Marc Fellous ;

Lin Shen ;

Thierry André , MD;

Elena Garralda ;

Aitana Ferrandiz ;